Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathologists | 7 | 2021 | 8 | 1.630 |
Why?
|
| Job Application | 1 | 2021 | 3 | 0.720 |
Why?
|
| Echinococcus multilocularis | 1 | 2015 | 1 | 0.500 |
Why?
|
| Neglected Diseases | 1 | 2015 | 2 | 0.500 |
Why?
|
| Echinococcus granulosus | 1 | 2015 | 2 | 0.500 |
Why?
|
| Echinococcosis | 1 | 2015 | 2 | 0.500 |
Why?
|
| Employment | 4 | 2021 | 49 | 0.400 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2011 | 9 | 0.360 |
Why?
|
| Virology | 1 | 2011 | 4 | 0.360 |
Why?
|
| Microarray Analysis | 1 | 2011 | 64 | 0.350 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 42 | 0.340 |
Why?
|
| Influenza, Human | 1 | 2011 | 85 | 0.330 |
Why?
|
| Internship and Residency | 3 | 2017 | 239 | 0.330 |
Why?
|
| Pathology, Clinical | 2 | 2019 | 11 | 0.330 |
Why?
|
| Bacteremia | 2 | 2019 | 80 | 0.290 |
Why?
|
| Pathology | 3 | 2017 | 8 | 0.290 |
Why?
|
| Escherichia coli | 2 | 2021 | 337 | 0.280 |
Why?
|
| Surveys and Questionnaires | 6 | 2021 | 971 | 0.280 |
Why?
|
| Professionalism | 2 | 2017 | 7 | 0.270 |
Why?
|
| International Cooperation | 1 | 2024 | 20 | 0.230 |
Why?
|
| Humans | 18 | 2024 | 28097 | 0.220 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2021 | 42 | 0.200 |
Why?
|
| Escherichia coli Infections | 2 | 2021 | 45 | 0.200 |
Why?
|
| Obstetric Labor, Premature | 1 | 2021 | 15 | 0.190 |
Why?
|
| Cervix Uteri | 1 | 2021 | 65 | 0.180 |
Why?
|
| Personnel Selection | 1 | 2021 | 7 | 0.180 |
Why?
|
| Professional Competence | 1 | 2021 | 37 | 0.180 |
Why?
|
| Career Choice | 1 | 2021 | 53 | 0.170 |
Why?
|
| Sexism | 1 | 2019 | 9 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 186 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 524 | 0.150 |
Why?
|
| Listeriosis | 1 | 2018 | 41 | 0.150 |
Why?
|
| Listeria monocytogenes | 1 | 2018 | 59 | 0.150 |
Why?
|
| Job Satisfaction | 1 | 2017 | 24 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2015 | 229 | 0.130 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 143 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 143 | 0.130 |
Why?
|
| Educational Measurement | 1 | 2016 | 127 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 297 | 0.120 |
Why?
|
| Global Health | 1 | 2015 | 51 | 0.120 |
Why?
|
| Genomics | 1 | 2015 | 123 | 0.110 |
Why?
|
| Curriculum | 1 | 2015 | 291 | 0.100 |
Why?
|
| Blood Specimen Collection | 1 | 2013 | 14 | 0.100 |
Why?
|
| HIV-1 | 1 | 2013 | 58 | 0.100 |
Why?
|
| Education, Medical, Graduate | 3 | 2017 | 108 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 21 | 0.090 |
Why?
|
| HIV Infections | 1 | 2013 | 159 | 0.090 |
Why?
|
| Career Mobility | 2 | 2019 | 7 | 0.080 |
Why?
|
| Aspergillus flavus | 1 | 2009 | 2 | 0.080 |
Why?
|
| Azoles | 1 | 2009 | 6 | 0.080 |
Why?
|
| Aspergillosis | 1 | 2009 | 11 | 0.080 |
Why?
|
| Sinusitis | 1 | 2009 | 11 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 521 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 2009 | 67 | 0.080 |
Why?
|
| Phylogeny | 2 | 2021 | 479 | 0.070 |
Why?
|
| Female | 6 | 2021 | 15156 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2021 | 885 | 0.070 |
Why?
|
| Mass Casualty Incidents | 1 | 2024 | 2 | 0.060 |
Why?
|
| Ireland | 1 | 2024 | 16 | 0.060 |
Why?
|
| United Kingdom | 1 | 2024 | 76 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2011 | 2546 | 0.060 |
Why?
|
| Military Personnel | 1 | 2024 | 47 | 0.050 |
Why?
|
| Adult | 3 | 2021 | 7740 | 0.050 |
Why?
|
| United States | 2 | 2019 | 2146 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 20 | 0.050 |
Why?
|
| Neonatal Sepsis | 1 | 2021 | 3 | 0.050 |
Why?
|
| Animals | 1 | 2015 | 10423 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 109 | 0.050 |
Why?
|
| Genome, Bacterial | 1 | 2021 | 70 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 148 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 330 | 0.040 |
Why?
|
| Middle Aged | 3 | 2018 | 7138 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 433 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2021 | 248 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 696 | 0.040 |
Why?
|
| Male | 3 | 2021 | 13491 | 0.040 |
Why?
|
| Multilocus Sequence Typing | 1 | 2019 | 2 | 0.040 |
Why?
|
| Virulence | 1 | 2019 | 151 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2018 | 67 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2018 | 29 | 0.040 |
Why?
|
| Immunization | 1 | 2018 | 120 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 847 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2021 | 1248 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 456 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 39 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 1191 | 0.030 |
Why?
|
| Faculty | 1 | 2017 | 62 | 0.030 |
Why?
|
| Oklahoma | 1 | 2018 | 1007 | 0.030 |
Why?
|
| Time Factors | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2733 | 0.030 |
Why?
|
| Viral Load | 1 | 2013 | 31 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2013 | 68 | 0.020 |
Why?
|
| Itraconazole | 1 | 2009 | 9 | 0.020 |
Why?
|
| Voriconazole | 1 | 2009 | 4 | 0.020 |
Why?
|
| Triazoles | 1 | 2009 | 16 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2009 | 125 | 0.020 |
Why?
|